Beijing Biostar Pharmaceuticals

CompanyChina

Beijing Biostar Pharmaceuticals develops one asset, in phase 2 (UTD2 in doxorubicin). Mostly small molecule acting on apoptosis and TUBB; based in China.

Assets
1
Furthest
Phase 2
Trials
1
Signals
1

Pipeline

1

  • UTD2

    Microtubule stabilizer (epothilone analog) promoting tubulin polymerization and cell cycle arrest.

    Phase 2Small moleculeApoptosisTUBBdoxorubicinsoft tissue sarcoma

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms2
  • Trials1
  • Signals1
  • Similar companies6

Updated 7 Oct 2026 · 4 sources

Intelligence